Overview

Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

This study will be an open-label, randomised, three-period, three-treatment, crossover study in healthy Japanese male and female of non-childbearing potential subjects, performed at a single study centre. The objective of the study is to assess the bioequivalence of ticagrelor orodispersible (OD) tablets when administered with water and without water and ticagrelor immediate-release (IR) tablets.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Ticagrelor